BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes

WALTHAM, Mass. & SAN FRANCISCO–(BUSINESS WIRE)–BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, announced today the launch of a collaboration aimed at uncovering molecular mechanisms underlying IO treatment response and treatment-related toxicity in advanced cancer patients and discovering actionable blood-based b
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks